Journal Article

Opportunities and challenges of mRNA technologies in development of dengue virus vaccine

Liu, Xiaoyang

2025

Overview

Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: ADE / Animals / Antibodies / Antibodies, Viral - immunology / Clinical trials / dengue / Dengue - immunology / Dengue - prevention & control / Dengue fever / Dengue hemorrhagic fever / Dengue Vaccines - genetics / Dengue Vaccines - immunology / Dengue Virus - genetics / Dengue Virus - immunology / DENV vaccine / FDA approval / Headaches / Humans / Immunity (Disease) / Immunology / Infections / Licenses / Mosquitoes / mRNA / mRNA vaccine / mRNA vaccines / Population / RNA, Messenger - genetics / RNA, Messenger - immunology / tropical disease / Tropical diseases / Vaccine development / Vaccine Development - methods / Vaccines / Vaccines, Synthetic - immunology / Viruses